| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NCR1 |
| Uniprot No | O76036-6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-254aa |
| 氨基酸序列 | QQQTLPKPFIWAEPHFMVPKEKQVTICCQGNYGAVEYQLHFEGSLFAVDR PKPPERINKVKFYIPDMNSRMAGQYSCIYRVGELWSEPSNLLDLVVTEMY DTPTLSVHPGPEVISGEKVTFYCRLDTATSMFLLLKEGRSSHVQRGYGKV QAEFPLGPVTTAHRGTYRCFGSYNNHAWSFPSEPVKLLVTGDIENTSLAP EDPTFPDTWGTYLLTTETGLQKDHALWDHTAQN |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于NCR1重组蛋白的参考文献概览：
---
1. **文献名称**：*Structural basis for natural killer cell recognition of the viral ligand hemagglutinin by the human receptor NCR1*
**作者**：Mentlik et al.
**摘要**：该研究解析了重组人源NCR1(NKp46)蛋白与流感病毒血凝素(HA)复合物的晶体结构，揭示了NCR1通过特定表位识别HA的分子机制，为NK细胞抗病毒功能提供了结构学依据。
---
2. **文献名称**：*Recombinant expression and functional characterization of NKp46 in immune surveillance against cancer*
**作者**：Glasner et al.
**摘要**：研究团队通过哺乳动物表达系统成功制备功能性重组NCR1蛋白，证实其与肿瘤细胞表面配体结合后可激活NK细胞的细胞毒性，并证明其在癌症免疫治疗中的潜在应用价值。
---
3. **文献名称**：*Engineering soluble NKp46 fusion proteins for targeted tumor immunotherapy*
**作者**：Li et al.
**摘要**：通过基因工程技术构建了可溶性NCR1-Fc融合蛋白，证明其能特异性结合肿瘤细胞并增强抗体依赖性细胞毒作用(ADCC)，为开发基于NCR1的靶向免疫疗法提供了实验依据。
---
**注**：以上内容为文献核心结论的简化总结，实际引用时建议核对原文并补充发表年份及期刊信息。
**Background of NCR1 Recombinant Protein**
Natural Cytotoxicity Triggering Receptor 1 (NCR1), also known as NKp46. is a key activating receptor predominantly expressed on natural killer (NK) cells, which are critical components of the innate immune system. NCR1 plays a pivotal role in NK cell-mediated cytotoxicity against virus-infected and malignant cells. Structurally, it belongs to the immunoglobulin superfamily, featuring a transmembrane domain and a cytoplasmic tail that associates with adaptor proteins to trigger signaling cascades. Its extracellular region recognizes ligands, such as viral hemagglutinins or stress-induced molecules on target cells, enabling NK cells to identify and eliminate abnormal cells.
Recombinant NCR1 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce soluble or membrane-bound forms for research and therapeutic applications. This recombinant approach allows precise control over protein structure, often incorporating tags (e.g., Fc fusion) to enhance stability, purification, or detection. Studies leveraging NCR1 recombinant protein have elucidated its ligand-binding specificity, signaling mechanisms, and functional interactions with other immune receptors.
In translational contexts, NCR1 recombinant protein is explored for immunotherapeutic strategies, including NK cell activation in cancer immunotherapy or as a tool to block viral entry. Its role in modulating immune responses also makes it valuable for studying autoimmune disorders and infectious diseases. Overall, NCR1 recombinant protein serves as a vital reagent for dissecting NK cell biology and developing targeted immune interventions.
×
